Gilead plans to develop Ouro’s lead drug candidate, gamgertamig, alongside a Belgian pharma company.

By Mariam Sunny March 23 (Reuters) - Gilead Sciences said on Monday it would buy privately held biotech firm Ouro Medicines ...

Gilead Sciences is paying $1.67 billion for a T-cell engager (TCE) company via a front-loaded deal that could also give new ...

OM336 is designed to enable rapid and deep B cell depletion following a limited subcutaneously administered treatment course.

Gilead said the deal would bolster its growing inflammation portfolio.

Gilead Sciences Inc. is in advanced talks to acquire Ouro Medicines, a closely held company testing novel antibody drugs ...

Gilead increased CEO Daniel O’Day's compensation by 20% in 2025 to $28.4 million, putting him among the highest-paid chief ...

Gilead acquired Arcellx to gain the development and marketing rights to anito-cel, for which GlobalData forecasts sales of ...

Gilead Sciences has built up its position in the hot area of T-cell engagers (TCEs) for autoimmune diseases with an agreement ...

California-based drugmaker takes advantage of surging share price to strike takeovers after a quiet couple of years ...

Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro MedicinesNew partnership structure ...